Successful eradication of acquired factor VIII inhibitors with rituximab: a report of two cases
These cases emphasize the efficacy and safety of rituximab in managing AHA. Given its potential benefits, further randomized controlled trials are warranted to evaluate rituximab's role as a first-line treatment. A structured monitoring protocol is recommended to ensure safe administration and manage potential side effects associated with immunosuppressive therapy.
Authors
- Israa Jawarneh
- Awni Alshurafa (ORCID: https://orcid.org/0000-0002-4454-5307)
- Anas Al-sadi
- Sarah Elkourashy (ORCID: https://orcid.org/0000-0002-5066-0125)
- Ma’in Abumuhfouz (ORCID: https://orcid.org/0009-0002-0204-1706)
- Ruba Y. Taha (ORCID: https://orcid.org/0000-0002-7941-5342)
Institutions
- King Abdullah University Hospital (JO)
- National Center for Cancer Care and Research (QA)
- Weill Cornell Medical College in Qatar (QA)
- Hamad Medical Corporation (QA)
Publication Details
- Journal
- Hematology
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1080/16078454.2024.2424521
- Citations
- 1
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.44
Funders
- Qatar National Library